Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

Cancer

Volumn 109, Issue 8, 2007, Pages 1556-1560

  Kantarjian, Hagop ^a   O'Brien, Susan ^a   Talpaz, Moshe ^b   Borthakur, Gautam ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Rios, Mary Beth ^a   Shan, Jianqin ^a   Giles, Francis ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chronic myelogenous leukemia; Imatinib mesylate failure; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; LONAFARNIB; NILOTINIB; TIPIFARNIB;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES;

EID: 34247248807     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22569     Document Type: Article

References (9)

1. O'Brien SG, Guilhot F, Larson RA, et al., for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
2. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood. 2006;108:1835-1840.
3. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478-1484.
4. Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979-1988.
5. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
6. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in the accelerated phase of chronic myelogenous leukemia - comparison with historical experience. Cancer. 2005;103:2099-2108.
7. Talpaz M, Silver R, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2531-2541;354:24.
9. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2541.